{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-071745","form_type":"8-K","ticker":"IXHL","cik":"0001873875","company_name":"Incannex Healthcare Inc.","filed_at":"2026-06-25T11:31:00+00:00","discovered_at":"2026-06-25T11:35:00.294746+00:00","generated_at":"2026-06-25T11:35:33.460465+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Incannex granted US patent covering IHL-42X for obstructive sleep apnea through 2040","bullets":["USPTO granted patent for IHL-42X composition and methods for OSA; baseline expiry 9 July 2040.","Company exploring patent term extension after potential FDA approval to lengthen exclusivity.","IHL-42X has FDA Fast Track designation, positive Phase II data; DReAMzz study nearing patient recruitment with site IRB approvals and DEA registrations.","CEO states patent validates IHL-42X as differentiated asset targeting billion-person OSA market with poor adherence."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-071745","json":"https://secwatch.observer/filing/0001213900-26-071745.json","markdown":"https://secwatch.observer/filing/0001213900-26-071745.md","text":"https://secwatch.observer/filing/0001213900-26-071745.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026071745/0001213900-26-071745-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1873875/000121390026071745/ea0295769-8k_incannex.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T11:35:33.460465+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}